M&A / Deals MSD-backed Ray locks in $125m to back eye drug pipeline Pharmaceutical TechnologyRay's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.M&A / DealsOphthalmologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Ray’s MSD and Novo Holdings-backed Series B will shed light on the potential of the company’s vision restoration gene therapy pipeline. M&A / DealsOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New data build case for Roche’s oral BTK drug for MSNext: FDA delays decision on Sanofi’s subcutaneous Sarclisa Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
